Main Article Content

Abstract

Background. SARS-CoV-2 virus, a type of Coronaviridae virus that affects people, is the
cause of COVID-19.This viral disease like any other diseases, the infection linked to this
one might be brought on by a parasite, virus, bacteria, or other kind of microbe.
Methods. Examining the level of antibodies in the serum of patients of anti- E. histolytica
IgA, IgG and IgM antibodies and anti-CMV IgG and IgM antibodies are measured by
immunoassay of patient's sera by ELISA system and whole blood was withdrawn to check
for bacteremia.
Results. As a result, 60 blood samples from COVID-19 patients were taken, along with 30
samples from healthy individuals, for testing to find antibodies against E. histolytica and
Cytomegalovirus. The patients were clinically and radiographically proven to have the
COVID-19. To screen for bacteremia, the entire blood was tested.
Conclusions. The results show a significant difference in the titration of E. histolyticaIgA antibody, IgG and IgM. COVID-19 patients with CMV-IgG antibody showed (100%) rate
of infection reporting a significant differences during the current study, while CMV-IgM
antibody showed (3.3%) rate of infection. Regarding bacteremia, all results of bacteria
detection in blood culture of Covid-19 patients were negative and there is no relationship
between the infection of COVID-19 and bacteremia.

Keywords

Entamoeba histolytica Cytomegalovirus Bacteria and COVID-19

Article Details

References

  1. - Yanagawa, Y., Nagata, N., Yagita, K., Watanabe, K., Okubo, H., Kikuchi, Y., Gatanaga, H., Oka, S., &
  2. Watanabe, K. (2021). Clinical Features and Gut Microbiome of Asymptomatic Entamoeba histolytica
  3. Infection. Clinical Infectious Diseases, 73(9), 3163–3171.
  4. - Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., Chen, Y., & Zhang, Y. (2020). COVID-19:
  5. immunopathogenesis and Immunotherapeutics. Signal Transduction and Targeted Therapy 5(1).
  6. - Hemphill, A., Müller, N., & Müller, J. (2019). Comparative pathobiology of the intestinal
  7. protozoan parasites giardia lamblia, Entamoeba histolytica, and Cryptosporidium parvum.
  8. Pathogens,8(3).
  9. - Ankri, S. (2021). Entamoeba histolytica—gut microbiota interaction: More than meets the eye.
  10. Microorganisms,9(3) ,1–12.
  11. - Mohammed Saba, A., Muhammad, A., Baba, J., Mustapha, A., & Hussaini, H. B. (2020).
  12. Prevalence Of Entamoeba Histolytica Infection Among Primary School Children In Five Selected
  13. Communities Of Wushishi Local Government Area, Niger State, Nigeria. Fudma Journal Of Sciences, 4(3),
  14. –667.
  15. - Chinese Center for Disease Control and Prevention.(2020). Technical
  16. documents for COVID-19 prevention and control. CCDC Weekly, 2 (19), 332-337.
  17. - Kiyoyama, T., Tokuda, Y., Shiiki, S., Hachiman, T., Shimasaki, T., & Endo, K. (2009). Isopropyl
  18. alcohol compared with isopropyl alcohol plus povidone-iodineas skin preparation for prevention of
  19. blood culture contamination. Journal of Clinical Microbiology, 47(1), 54–58.
  20. - Ghosh, S., Padalia, J., & Moonah, S. (2019). Tissue Destruction Caused by Entamoeba histolytica
  21. Parasite: Cell Death, Inflammation, Invasion, and the Gut Microbiome.Current Clinical Microbiology
  22. Reports ,6( 1), 51–57.
  23. - Zorbozan, O. (2022). The Impact of COVID-19 Pandemic on Access to Healthcare: The
  24. Experience of the Diagnostic Parasitology Laboratory of Ege University. Turkish Journal of Parasitology,
  25. (2), 124–128.
  26. - Azmi, N., & Othman, N. (2021). Entamoeba histolytica: Proteomics bioinformatics reveal
  27. predictive functions and protein–protein interactions of differentially abundant membrane and cytosolic
  28. proteins. Membranes, 11(6).
  29. - Elsaftawy, E., Wassef, R., & Amin, N. (2021). Can endemic parasitic diseases and/or vectors play
  30. a role in the COVID-19 pandemic?, parasitologists united journal, 14(1), 7–14.
  31. - Abuljadayel, D., Atef, A., Al-Matary, M., Edris, S., Al-Quwaie, D. A. H., Alsubhi, N. H., Al-Hindi, R.
  32. R., Sabir, J. S. M., Hall, N., & Bahieldin, A. (2020). Detection of a negative biomarker for amebiasis
  33. (Entamoeba histolytica) in the human gut mycobiome. Applied Ecology and Environmental Research,
  34. (2), 2363–2394.
  35. - Mahmood, N., & AL-Ghazal, A. (2020). Prevalence of Cytomegalovirus and its Roles in Cytokines
  36. Stimulation in Immunocompromised Patients in Mosul City. Rafidain journal of science, 29, 17-27. Iraq,
  37. (3), 17–27.
  38. - Flaih, M. H., Khazaal, R. M., Kadhim, M. K., Hussein, K. R., & Alhamadani, F. A. B. (2021). The
  39. epidemiology of amoebiasis in Thi-Qar Province, Iraq (2015-2020): Differentiation of Entamoeba
  40. histolytica and Entamoeba dispar using nested and real-time polymerase chain reaction. Epidemiology
  41. and Health, 43.
  42. - Hamza, D.M., Malaa, S.F., & Alaaraji, K.K. (2021). Real-Time-PCR Assay Based on
  43. Phosphoglycerate Kinase Gene for Detection of Entamoeba histolytica Trophozoites in Stool Samples in
  44. Holy Karbala, Iraq. Medico-Legal Update, 21, 1656-1664.
  45. - Mahmood, S. A. F., & Bakr, H. M. (2020). Molecular Identification and Prevalence of Entamoeba
  46. histolytica, Entamoeba dispar and Entamoeba moshkovskii in Erbil City, Northern Iraq. Polish journal of
  47. microbiology, 69(3), 263–272.
  48. - Al-Salehy, Z.K., & Mohammad, Z.A. (2020). Relationship between fecal calprotectin and other
  49. immunological parameters in diarrheal children infected with Entamoeba histolytica and pathogenic
  50. bacteria in thi-qar province,Iraq. Plant Archives,20 , 1089-1095.
  51. - Afar, J. ’, Adam, S., Yahaya, M. G., Nas, F. S., Mu’azu, L., & Ali, M. (2021). Determination of
  52. prevalence rate of Entamoeba histolytica among children diagnosed with acute diarrhea in kano,
  53. Nigeria. Journal of the Medical Sciences, 9,16-18.
  54. - Smith, A.P., & Pawelec, G. (2020). Possible causes of disparities in the risk and outcomes of
  55. COVID-19: Cytomegalovirus and aged immune phenotype. Journal of Clinical and Translational
  56. Research, 6, 92 - 93.
  57. - Ibrahim, M. N. (2021). Seroprevalence of cytomegalovirus antibodies among COVID-19 patients.
  58. Biomedical and Pharmacology Journal, 14(3), 1561–1565.
  59. - Alanio, C., Verma, A., Mathew, D., Gouma, S., Liang, G., Dunn, T., Oldridge, D. A., Weaver, J.,
  60. Kuri-Cervantes, L., Pampena, M. B., Betts, M. R., Collman, R. G., Bushman, F. D., Meyer, N. J., Hensley, S.
  61. E., Rader, D., Wherry, E. J., Baxter, A. E., D’Andrea, K., … Vanderbeck, A. N. (2022). Cytomegalovirus
  62. Latent Infection is Associated with an Increased Risk of COVID-19-Related Hospitalization. The Journal
  63. of Infectious Diseases,10,1-11.
  64. - Gatto, I., Biagioni, E., Coloretti, I., Farinelli, C., Avoni, C., Caciagli, V., Busani, S., Sarti, M.,
  65. Pecorari, M., Gennari, W., Guaraldi, G., Franceschini, E., Meschiari, M., Mussini, C., Tonelli, R., Clini, E.,
  66. Cossarizza, A., Girardis, M., Girardis, M., … Serpini, G. F. (2022). Cytomegalovirus blood reactivation in
  67. COVID-19 critically ill patients: risk factors and impact on mortality. Intensive Care Medicine,48,706-
  68. - Lantos, P. M., Hoffman, K., Permar, S. R., Jackson, P., Hughes, B. L., & Swamy, G. K. (2017).
  69. Geographic disparities in cytomegalovirus infection during pregnancy. Journal of the Pediatric Infectious
  70. Diseases Society, 6(3), 55– 61.
  71. - Hemmersbach-Miller, M., Alexander, B. D., Pieper, C. F., & Schmader, K. E. (2020). Age matters:
  72. older age as a risk factor for CMV reactivation in the CMV serostatus–positive kidney transplant
  73. recipient. European Journal of Clinical Microbiology & Infectious Diseases,39(3), 455–463.
  74. - A.ALTaie, A., A.Ibraheem, M., & A. Muhammad, M. (2019). Detection of Cytomegalovirus by
  75. ELISA Technique in Rheumatoid Arthritis Patients in Mosul / Iraq. The 6th International Conference of
  76. Biotechnology, Environment and Engineering Sciences. 141–147.
  77. - Esquer Garrigos, Z., Wingler, M.J., Svoronos, P., Vijayvargiya, P., Goodman-Meza, D., O’Horo, J.C.,
  78. Navalkele, B.D., Cretella, D.A., Frame, I.J., Parham, J.J., & Lucar, J. (2021). Increased rates of blood
  79. culture contamination during the coronavirus disease 2019 pandemic. Infection Control and Hospital
  80. Epidemiology, 1 - 3.
  81. - Gülseren, Y. D., Esenkaya Taşbent, F., & Ozdemir, M. (2019). Investigation of CMV and Rubella
  82. Seroprevalence and Age Related Distribution in Pregnant Women. Journal of Turkish Microbiology
  83. Society, 49(3):154-161.
  84. - Siennicka, J., Dunal-Szczepaniak, M., Trzcińska, A., Godzik, P., & Rosińska, M. (2016). High
  85. Seroprevalence of CMV Among Women of Childbearing Age Implicates High Burden of Congenital
  86. Cytomegalovirus Infection in Poland. Polish journal of microbiology, 65, 425 - 432.
  87. - Ait Zirri, K., Elfersani, F., Amrani, A., & Soraa, N. (2021). Microbial Coinfections in Patients with
  88. SARS-CoV2. International Journal of Medical Science and Health Research, 05(02), 260–266.
  89. - Mahmoudi, H.(2020)Bacterial co-infections and antibiotic resistance in patients with COVID19,15.
  90. - Mahmoudi, H. (2020). Bacterial co-infections and antibiotic resistance in patients with COVID19. GMS Hygiene and Infection Control, 15.
  91. - Mormeneo Bayo, S., Palacián Ruíz, M. P., Moreno Hijazo, M., & Villuendas Usón, M. C.
  92. (2022).Bacteremia during COVID-19 pandemic in a tertiary hospital in Spain. Infectious Diseases and
  93. Clinical Microbiology,40(4), 183–186.
  94. - Ibrahim, H.M., Mohamed, A.M., & Mabrook, H. (2021). Hematological and biochemical effects of
  95. Toxoplasma gondii, Entamoeba histolytica, and Schistosoma infection among Hepatitis C virus patients
  96. from Menoufia Province, Egypt. Biomedical and Biotechnology Research Journal (BBRJ),5(3), 295–301.
  97. - Thelen, J.M., Buenen, A.G., van Apeldoorn, M.J., Wertheim, H.F., Hermans, M.H., & Wever, P.C.
  98. (2021). Community-acquired bacteraemia in COVID-19 in comparison to influenza A and influenza B: a
  99. retrospective cohort study. BMC Infectious Diseases, 21(1).
  100. - Koksal, I., Aksoy, F., Kaya, S., Taş, M., & Yılmaz, G. (2019). 2310. No Recurrence in Recovered
  101. People with CCHF: A Cross-Sectional Study From Turkey, Preliminary Report. Open Forum Infectious
  102. Diseases, 6, S792 - S792.
  103. - Suarez-de-la-Rica, A., Serrano, P.M., de-la-Oliva, R., Sánchez-Díaz, P., Molinero, P., FalcesRomero, I., Ferrando, C., Rello, J., & Maseda, E. (2021). Secondary infections in mechanically ventilated
  104. patients with COVID-19: An overlooked matter? Spanish Journal of Chemotherapy, 34, 330 - 336.
  105. - Sabeeh F.A and Khalaf A.Kh. (2022). MOLECULAR DIVERSITY FOR ENTAMOEBA HISTOLYTICA
  106. VIRULENCE FACTOR GENES ISOLATED FROM PATIENTS WITH AMOEBIC DYSENTERY . Biochem. Cell.
  107. Arch. Vol. 22, No. 2, pp. 3441-3447.
  108. - Abed A.A. and Khalaf A.Kh. (2023) . Serological Detection for Toxoplasmosis among Patients
  109. with Covid-19 in Thi-Qar Province. Archives of Razi Institute, Vol. 78, No. 2 (2023) 715-720.
  110. - Hameed F.A. and Khalaf A.Kh. (2022). Serological detection for Entamoeba histolytica among
  111. cancer patients suffering from diarrhea in Thi-Qar province/ Southern Iraq. Journal of Science
  112. (UTJsci),Volume (9), No.2.
  113. - Sabeeh F.A and Khalaf A.Kh. (2022).Biochemical study for Amoebic dysentery in patients with
  114. Entamoeba histolytica in Thi-Qar province/southern Iraq. BASRAH JOURNAL OF VETERINARY
  115. RESEARCH, 21(S1):14-26

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)